A carregar...
Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study
AIMS: To compare the pharmacodynamic effects of the highest approved doses of the sodium glucose co‐transporter 2 (SGLT2) inhibitors canagliflozin and dapagliflozin on urinary glucose excretion (UGE), renal threshold for glucose excretion (RT(G)) and postprandial plasma glucose (PPG) excursion in he...
Na minha lista:
| Publicado no: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Ltd
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6680204/ https://ncbi.nlm.nih.gov/pubmed/25421015 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12418 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|